Prescription Drugs
This year's program opens with a hard-edged look at prescription drug policy, where debates over intellectual property, MFN pricing, PBMs, and the future of generics and biosimilars are converging into one of the most consequential policy fights heading into the midterms. Featuring leaders across government, industry, and patient advocacy. The discussion reflects a system under pressure to reconcile innovation with affordability, and rhetoric with results.








